ClinicalTrials.gg

Program

Varenicline

Also written as “varenicline”, “Varenicline Tartrate” and “varenicline (CP-526,555)”.

Its studies are mostly in Smoking Cessation · Dry Eye Syndromes · Smoking · Trigeminal Neuralgia · Cigarette Smoking, led by 6 companies.

Furthest: phase 4, since Jan 3, 200844 company-led studies, 1 open or runningNext primary completion: Feb 2029 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Pfizer320 open or runningphase 4since Jan 3, 2008Aug 29, 2005none ahead
Viatris60 open or runningphase 3since Jul 25, 2019Aug 15, 2018none ahead
Corxel Pharmaceuticals20 open or runningphase 3since May 13, 2022May 13, 2022none ahead
Rose Research Center20 open or runningphase 4since Jun 6, 2019Jun 6, 2019none ahead
Kriya Therapeutics11 open or runningphase 2since Apr 17, 2026Apr 17, 2026Feb 2029phase 2 · NCT07596485
SRI International10 open or runningno phasesince Mar 8, 2006Mar 8, 2006none ahead

Also a collaborator on its studies: GlaxoSmithKline.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

Before these, 30 studies since Aug 29, 2005.

  1. Jun 8, 2011Phase 4 study in Smoking CessationPfizer · NCT01370356 · 1,510 enrolled · United States, Australia, Canada and more
  2. Oct 14, 2011Phase 4 study in Smoking CessationPfizer · NCT01456936 · 8,144 enrolled · United States, Argentina, Australia and more
  3. Apr 6, 2012Phase 4 study in Smoking CessationPfizer · NCT01574703 · 4,595 enrolled · United States, Argentina, Australia and more
  4. Aug 15, 2018Viatris's first study: phase 2 study in Dry Eye SyndromesNew to ViatrisViatris · NCT03636061 · 182 enrolled · United States
  5. Sep 26, 2018Phase 2 study in Dry Eye SyndromesViatris · NCT03688802 · 18 enrolled · United States
  6. Mar 11, 2019Phase 2 study in Dry Eye SyndromesViatris · NCT03873246 · 123 enrolled · Mexico
  7. Jun 6, 2019Rose Research Center's first study: phase 4 study in Smoking CessationNew to Rose Research CenterRose Research Center · NCT04188106 · 26 enrolled · United States
  8. Jul 25, 2019Phase 3 study in Dry Eye SyndromesViatris · NCT04036292 · 758 enrolled · United States
  9. Aug 27, 2019Phase 1 study in Healthy SubjectsViatris · NCT04072146 · 22 enrolled · United States
  10. Dec 4, 2019Phase 3 study in Smoking CessationRose Research Center · NCT04210180 · 25 enrolled · United States
  11. Jun 28, 2021Phase 2 study in Neurotrophic KeratopathyViatris · NCT04957758 · 113 enrolled · United States
  12. May 13, 2022Corxel Pharmaceuticals's first study: phase 3 study in Dry Eye SyndromesNew to Corxel PharmaceuticalsCorxel Pharmaceuticals · NCT05378945 · 340 enrolled · China
  13. Sep 27, 2022Phase 1 study in Dry Eye SyndromesCorxel Pharmaceuticals · NCT05576415 · 9 enrolled · China
  14. Apr 17, 2026Kriya Therapeutics's first study: phase 2 study in Trigeminal NeuralgiaNew to Kriya TherapeuticsKriya Therapeutics · NCT07596485 · 24 planned · Canada

Ahead

  1. Feb 2029Primary completion: phase 2 study in Trigeminal NeuralgiaKriya Therapeutics · NCT07596485

TargetBeta

“Neuronal acetylcholine receptor; alpha4/beta2 agonist; Neuronal acetylcholine receptor; alpha4/beta2 partial agonist”ChEMBL 37, by rule

Other programs on the same two targets

ProgramCompanyFurthest phaseStudies
cytisineruleAchieve Life Sciencesphase 313

Studies

All 44 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT07596485Trigeminal Neuralgia · Canada2RecruitingKriya TherapeuticsFeb 202924
NCT05576415Dry Eye Syndromes · China1CompletedCorxel PharmaceuticalsApr 27, 20239
NCT05378945Dry Eye Syndromes · China3CompletedCorxel PharmaceuticalsApr 4, 2023340
NCT04957758Neurotrophic Keratopathy · United States2CompletedViatrisJan 27, 2023113
NCT04210180Smoking Cessation · United States3CompletedRose Research CenterOct 14, 202025
NCT04072146Healthy Subjects · United States1CompletedViatrisNov 15, 201922
NCT04036292Dry Eye Syndromes · United States3CompletedViatrisApr 10, 2020758
NCT04188106Smoking Cessation · United States4CompletedRose Research CenterDec 15, 201926
NCT03873246Dry Eye Syndromes · Mexico2CompletedViatrisJan 7, 2020123
NCT03688802Dry Eye Syndromes · United States2CompletedViatrisSep 30, 201918
NCT03636061Dry Eye Syndromes · United States2CompletedViatrisSep 26, 2018182
NCT01574703Smoking Cessation · United States, Argentina, Australia and more4CompletedPfizerJul 20154,595
NCT01456936Smoking Cessation · United States, Argentina, Australia and more4CompletedPfizerJan 20158,144
NCT01370356Smoking Cessation · United States, Australia, Canada and more4CompletedPfizerJul 20131,510
NCT01312909Smoking Cessation · United States, Canada, Georgia and more4CompletedPfizerJan 2018312
NCT01244061Smoking Cessation · United States, Australia, Belgium and more4CompletedPfizerNov 2012498
NCT01078298Smoking Cessation · United States, Bosnia and Herzegovina, Croatia and more4CompletedPfizerJun 2012525
NCT00889720Smoking Cessation · France, Italy4CompletedPfizerJul 201016
NCT00749944Smoking Cessation · United States4CompletedPfizerJul 2009110
NCT00744978Alzheimer Disease · Korea, Republic of2CompletedPfizerNov 201066
NCT00743847Schizophrenia2WithdrawnPfizerNov 20090
NCT00717093Tobacco Use Cessation · Norway, Sweden4CompletedPfizerApr 2009432
NCT00694044Healthy · United States1CompletedPfizerJun 200850
NCT00691483Smoking Cessation · United States, Argentina, Brazil and more4CompletedPfizerSep 2009659
NCT00661765Smoking Cessation · United States1CompletedPfizerJun 200818
NCT00644969Smoking Cessation · United States, Canada3CompletedPfizerApr 2010128
NCT00635401Smoking · Japan2CompletedPfizer30
NCT00594204Smoking Cessation · Brazil, Colombia, Costa Rica and more4CompletedPfizerJun 2009593
NCT00527150Smoking Cessation · United States1CompletedPfizerFeb 200848
NCT00463918Smoking Cessation · United States, United Kingdom1CompletedPfizer73
NCT00452894Smoking · China1CompletedPfizer14
NCT00371813Smoking Cessation · China, Singapore, Thailand3CompletedPfizer334
NCT00301145Unspecified Adult Solid Tumor, Protocol Specific · United States–CompletedSRI InternationalJun 20081,200
NCT00282984Smoking Cessation · United States, Argentina, Australia and more3CompletedPfizerNov 2007714
NCT00150254Smoking Cessation · United States2CompletedPfizer625
NCT00150241Smoking Cessation · United States2CompletedPfizer625
NCT00150228Smoking Cessation · United States2CompletedPfizer300
NCT00143364Smoking Cessation · United States3CompletedPfizer1,005
NCT00143325Smoking Cessation · United States, Belgium, France and more3CompletedPfizer730
NCT00143299Smoking Cessation · United States, Australia3CompletedPfizer375
NCT00143286Smoking Cessation · United States, Canada, Czech Republic and more3CompletedPfizer2,000
NCT00141206Smoking Cessation · United States3CompletedPfizer1,005
NCT00141167Smoking Cessation · Korea, Republic of, Taiwan3CompletedPfizer250
NCT00139750Smoking Cessation · Japan2CompletedPfizer600

How it is read

Names in the registry

  • “varenicline”, 11 entries
  • “Varenicline Tartrate”, 7 entries
  • “Varenicline”, 6 entries
  • “varenicline (CP-526,555)”, 6 entries
  • “CP-526,555 (varenicline)”, 4 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.